• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Adcetris (brentuximab vedotin)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Adcetris (brentuximab vedotin)

  • Profile

Profile

Contact Information

Contact: Seagen
Website: https://www.adcetris.com/

Currently Enrolling Trials

    Show More

    Adcetris (brentuximab vedotin) - 2 indications

    Scroll down for more information on each indication:

    Classical Hodgkin lymphoma and Anaplastic large cell lymphoma; approved in August of 2011

    General Information

    Adcetris (brentuximab vedotin) is an antibody-drug conjugate comprised of an anti-CD30 antibody joined by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. Brentuximab vedotin is designed to be stable in the bloodstream, but to release MMAE upon internalization into CD30-expressing tumor cells, resulting in a targeted cell-killing effect.

    Adcetris is specifically approved for the following:

    Classical Hodgkin lymphoma (cHL)

    • Adult patients with previously untreated Stage III or IV cHL, in combination with doxorubicin, vinblastine, and dacarbazine
    • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation
    • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
    • Pediatric patients 2 years and older with previously untreated high risk cHL in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide

    Anaplastic large cell lymphoma

    • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone
    • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen
    • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy

    Adcetris is supplied as a solution for intravenous infusion administered over 30 minutes. Scroll down for recommended dosing/administration for each indication. 

    Mechanism of Action

    Adcetris (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) consisting of three components: 1) the chimeric IgG1 antibody cAC10, specific for human CD30, 2) the microtubule disrupting agent MMAE, and 3) a protease-cleavable linker that covalently attaches MMAE to cAC10.

    Side Effects

    Adverse events associated with the use of Adcetris may include, but are not limited to, the following:

    • neutropenia
    • peripheral sensory neuropathy
    • fatigue
    • nausea
    • anemia
    • upper respiratory tract infection
    • diarrhea
    • pyrexia
    • rash
    • thrombocytopenia
    • cough
    • vomiting

    The Adcetris drug label comes with the following Boxed Warning: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in Adcetris-treated patients.

    Indication 1: Classical Hodgkin lymphoma (cHL)

    Dosing/Administration

    The recommended dosage as monotherapy for adult patients is 1.8 mg/kg up to a maximum of 180 mg every 3 weeks

    The recommended dosage in combination with chemotherapy for adult patients with previously untreated Stage III or IV cHL is 1.2 mg/kg up to a maximum of 120 mg every 2 weeks for a maximum of 12 doses

    The recommended dosage in combination with chemotherapy for pediatric patients 2 years and older with previously untreated high risk cHL is 1.8 mg/kg up to a maximum of 180 mg every 3 weeks for a maximum of 5 doses

    Clinical Trial Results
    The FDA approval of Adcetris for Hodgkin lymphoma was based on an open-label, single-arm, multicenter trial.The trial enrolled 102 subjects with HL who relapsed after autologous stem cell transplant. The subjects were treated with 1.8 mg/kg of Adcetris intravenously over 30 minutes every three weeks. Efficacy was based on overall response rate (ORR = complete remission [CR] + partial remission [PR]) and duration of response. The ORR was 73% and the median duration of response was 6.7 months.

    Indication 2 - Systemic Anaplastic Large Cell Lymphoma

    Dosing/Administration

    The recommended dosage as monotherapy for adult patients is 1.8 mg/kg up to a maximum of 180 mg every 3 weeks

    The recommended dosage in combination with chemotherapy for adult patients with previously untreated PTCL is 1.8 mg/kg up to a maximum of 180 mg every 3 weeks for 6 to 8 doses

    Clinical Trial Results
    The FDA approval of Adcetris for systemic anaplastic large cell lymphoma was based on an open-label, single-arm, multicenter trial. The trial enrolled 58 subjects who had relapsed after prior therapy. The subjects received 1.8 mg/kg of Adcetris administered intravenously over 30 minutes every three weeks. Efficacy was based on overall response rate (ORR = complete remission [CR] + partial remission [PR]) and duration of response. The ORR was 86% and the median duration of response was 12.6 months.

    Approval Date: 2011-08-01
    Company Name: Seagen
    Back to Listings

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • MAGI East 2023

      MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

    • Complexity-360x240.png

      Phase 3 Trials Significantly Rising in Complexity, Says CSDD

    • Quality Level Scale

      Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

    • DE&I

      Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing